[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Marino et al., 2018 - Google Patents

Thymic Neoplasm

Marino et al., 2018

Document ID
6154815464892809926
Author
Marino M
Facciolo F
Shen Y
Alessandrini G
Girard N
Publication year
Publication venue
The Mediastinal Mass: A Multidisciplinary Approach

External Links

Snippet

The variety of tumors originating in the thymus partially reflects the main cellular types present in the organ, ie, epithelial and lymphoid cells. However, in the anterior mediastinum along with the thymus, several other structures and ectopic tissues are located, giving rise to …
Continue reading at link.springer.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Similar Documents

Publication Publication Date Title
DeLellis et al. Primary hyperparathyroidism: a current perspective
Wright Management of thymomas
Chang et al. Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer
Kayani et al. A review of the surgical management of extrathoracic solitary fibrous tumors
MacGregor et al. Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now
von Dobschuetz et al. A registry-based study of thyroid paraganglioma: histological and genetic characteristics
Wu et al. Mediastinal follicular dendritic cell sarcoma: a rare, potentially under-recognized, and often misdiagnosed disease
Zhang et al. Analysis of clinicopathological features and prognostic factors of desmoplastic small round cell tumor
Sun et al. Controversies in rectal cancer treatment and management
Boutrid et al. TTF-1 positive primary small cell carcinoma of the breast: a case report and review of the literature
Ibrahim et al. Primary Hepatic Neuroendocrine Tumor with Unusual Thyroid Follicular‐Like Morphologic Characteristics
Rios et al. Multidimensional imaging of breast cancer
Wolpert et al. Ewing’s Sarcoma as a Second Malignancy in Long‐Term Survivors of Childhood Hematologic Malignancies
Righi et al. Primary sclerosing epithelioid fibrosarcoma of the spine: a single‐institution experience
Zarnescu et al. A challenging case of primary breast Hodgkin's lymphoma
Wani et al. Unraveling molecular signatures in rare bone tumors and navigating the cancer pathway landscapes for targeted therapeutics
Marino et al. Thymic Neoplasm
Pancer et al. A thyroid gland with over 30 foci of papillary thyroid carcinoma with activating BRAF V600E mutation
Khan et al. A rare case report of malignant peripheral nerve sheath tumor involving both the small bowel and large bowel
Azizun-Nisa et al. Primary renal leiomyosarcoma
Siddiqui et al. Mantle cell lymphoma in the thyroid: a rare presentation
Saravanan et al. Expression of cell surface zinc transporter LIV1 in triple negative breast cancer is an indicator of poor prognosis and therapy failure
Chiang et al. Pleural “drop metastases” 21 years after resection of a thymoma
Dasappa et al. Myeloid sarcoma as the first sign of progression of chronic myeloid leukemia in medullary chronic phase: experience from a Tertiary Cancer Centre in Southern India
Panel 32 nd Congress of the ESP and XXXIII International Congress of the IAP